These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 27286449

  • 21. Genomic regulation of invasion by STAT3 in triple negative breast cancer.
    McDaniel JM, Varley KE, Gertz J, Savic DS, Roberts BS, Bailey SK, Shevde LA, Ramaker RC, Lasseigne BN, Kirby MK, Newberry KM, Partridge EC, Jones AL, Boone B, Levy SE, Oliver PG, Sexton KC, Grizzle WE, Forero A, Buchsbaum DJ, Cooper SJ, Myers RM.
    Oncotarget; 2017 Jan 31; 8(5):8226-8238. PubMed ID: 28030809
    [Abstract] [Full Text] [Related]

  • 22. Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
    Yoshizawa K, Nozaki S, Kitahara H, Kato K, Noguchi N, Kawashiri S, Yamamoto E.
    Oncol Rep; 2011 Dec 31; 26(6):1555-60. PubMed ID: 21833477
    [Abstract] [Full Text] [Related]

  • 23. Targeting uPAR with antagonistic recombinant human antibodies in aggressive breast cancer.
    LeBeau AM, Duriseti S, Murphy ST, Pepin F, Hann B, Gray JW, VanBrocklin HF, Craik CS.
    Cancer Res; 2013 Apr 01; 73(7):2070-81. PubMed ID: 23400595
    [Abstract] [Full Text] [Related]

  • 24. CYR61 confers chemoresistance by upregulating survivin expression in triple-negative breast cancer.
    Kim H, Son S, Ko Y, Lim H, Lee J, Lee KM, Shin I.
    Carcinogenesis; 2024 Jul 08; 45(7):510-519. PubMed ID: 38446998
    [Abstract] [Full Text] [Related]

  • 25. Nafamostat Mesylate in Combination with the Mouse Amino-Terminal Fragment of Urokinase-Human Serum Albumin Improves the Treatment Outcome of Triple-Negative Breast Cancer Therapy.
    Zhou Y, Yu S, Chen D, Li H, Xu P, Yuan C, Jiang L, Huang M.
    Mol Pharm; 2023 Feb 06; 20(2):905-917. PubMed ID: 36463525
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
    Kren BT, Unger GM, Abedin MJ, Vogel RI, Henzler CM, Ahmed K, Trembley JH.
    Breast Cancer Res; 2015 Feb 06; 17():19. PubMed ID: 25837326
    [Abstract] [Full Text] [Related]

  • 29. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
    Maeda T, Nakanishi Y, Hirotani Y, Fuchinoue F, Enomoto K, Sakurai K, Amano S, Nemoto N.
    Med Mol Morphol; 2016 Mar 06; 49(1):11-21. PubMed ID: 26009308
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
    Byerly J, Halstead-Nussloch G, Ito K, Katsyv I, Irie HY.
    Breast Cancer Res; 2016 Sep 23; 18(1):95. PubMed ID: 27663795
    [Abstract] [Full Text] [Related]

  • 32. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
    Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brünner N, Jänicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG.
    Cancer Res; 2000 Feb 01; 60(3):636-43. PubMed ID: 10676647
    [Abstract] [Full Text] [Related]

  • 33. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
    Bahnassy A, Mohanad M, Ismail MF, Shaarawy S, El-Bastawisy A, Zekri AR.
    Exp Mol Pathol; 2015 Oct 01; 99(2):303-11. PubMed ID: 26232605
    [Abstract] [Full Text] [Related]

  • 34. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
    Costantini V, Sidoni A, Deveglia R, Cazzato OA, Bellezza G, Ferri I, Bucciarelli E, Nenci GG.
    Cancer; 1996 Mar 15; 77(6):1079-88. PubMed ID: 8635127
    [Abstract] [Full Text] [Related]

  • 35. Identification of Specific miRNA Signature in Paired Sera and Tissue Samples of Indian Women with Triple Negative Breast Cancer.
    Thakur S, Grover RK, Gupta S, Yadav AK, Das BC.
    PLoS One; 2016 Mar 15; 11(7):e0158946. PubMed ID: 27404381
    [Abstract] [Full Text] [Related]

  • 36. The Role and Mechanism of CRT0066101 as an Effective Drug for Treatment of Triple-Negative Breast Cancer.
    Liu Y, Wang Y, Yu S, Zhou Y, Ma X, Su Q, An L, Wang F, Shi A, Zhang J, Chen L.
    Cell Physiol Biochem; 2019 Mar 15; 52(3):382-396. PubMed ID: 30845378
    [Abstract] [Full Text] [Related]

  • 37. CTPS1 promotes malignant progression of triple-negative breast cancer with transcriptional activation by YBX1.
    Lin Y, Zhang J, Li Y, Guo W, Chen L, Chen M, Chen X, Zhang W, Jin X, Jiang M, Xiao H, Wang C, Song C, Fu F.
    J Transl Med; 2022 Jan 06; 20(1):17. PubMed ID: 34991621
    [Abstract] [Full Text] [Related]

  • 38. Silencing Y-box binding protein-1 inhibits triple-negative breast cancer cell invasiveness via regulation of MMP1 and beta-catenin expression.
    Lim JP, Nair S, Shyamasundar S, Chua PJ, Muniasamy U, Matsumoto K, Gunaratne J, Bay BH.
    Cancer Lett; 2019 Jun 28; 452():119-131. PubMed ID: 30905819
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
    Grøndahl-Hansen J, Christensen IJ, Briand P, Pappot H, Mouridsen HT, Blichert-Toft M, Danø K, Brünner N.
    Clin Cancer Res; 1997 Feb 28; 3(2):233-9. PubMed ID: 9815678
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.